Quantcast

Latest thyroid cancer Stories

2014-07-07 08:22:14

-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival in patients with RAI-refractory differentiated thyroid cancer compared to placebo in the Phase III DECISION trial TORONTO, July 7, 2014 /CNW/ - Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally...

2014-07-05 23:01:25

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication. New York, NY (PRWEB) July 05, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to...

2014-07-03 08:23:28

- Decisions to Cover Afirma for Use in Thyroid Cancer Diagnosis Bring Total Number of "Blues" Covered Lives to More than 10 Million - SOUTH SAN FRANCISCO, Calif., July 3, 2014 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that two Blue Cross Blue Shield (BCBS)-affiliated organizations, Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, have issued positive coverage policies for the company's...

2014-05-31 08:20:45

Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). Progression-free survival with lenvatinib was extended significantly compared to placebo (HR=0.21, [99% CI: 0.14-0.31]; p<0.0001). The median...

2014-05-19 23:04:54

Thyroid cancer increased from 14th to 5th most common cancer in women over last 20 years Fremont, California (PRWEB) May 19, 2014 The dramatic increase in the incidence of thyroid cancer worldwide over the past three decades likely relates to modifiable behavioral or environmental factors, as opposed to improved diagnostic capability, according to researchers at the Cancer Prevention Institute of California (CPIC) and their colleague at the Stanford University School of Medicine....

Scientists Seek Answers To Questions About Thyroid Cancer
2014-05-19 03:54:45

Jessica Nimon, NASA The multi-national efforts that go into research aboard the International Space Station show that working together can yield results with universal benefits. This is especially the case when talking about human health concerns such as cancer. Researchers make use of the microgravity environment aboard the space station to seek answers to questions about the nature of cancer cells. With the Microgravity on Human Thyroid Carcinoma Cells (Cellbox-Thyroid) study, recently...

2014-05-17 23:01:16

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and thyroid cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) May 17, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and other product liability claims involving a class of diabetes drugs called incretin mimetics continue to mount in a federal multidistrict litigation now underway in U.S. District Court, Southern District of...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-13 08:31:36

SOUTH SAN FRANCISCO, Calif., May 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. The Afirma Malignancy Classifiers comprise genomic tests for...

2014-05-06 08:34:15

SOUTH SAN FRANCISCO, Calif., May 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that four abstracts supporting the use of the company's Afirma Malignancy Classifiers and enhancing its overall Afirma solution will be presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Congress taking place May 14-18, 2014 in Las Vegas. Veracyte developed the Afirma Malignancy Classifiers to further expand the Afirma...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.